The estimated Net Worth of James S Scibetta is at least $354 Thousand dollars as of 19 August 2019. Mr. Scibetta owns over 22,971 units of Aquestive Therapeutics Inc stock worth over $156,593 and over the last 14 years he sold AQST stock worth over $85,167. In addition, he makes $112,497 as Independent Director at Aquestive Therapeutics Inc.
James has made over 16 trades of the Aquestive Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 22,971 units of AQST stock worth $87,060 on 19 August 2019.
The largest trade he's ever made was exercising 25,000 units of Aquestive Therapeutics Inc stock on 15 August 2016 worth over $40,250. On average, James trades about 5,115 units every 54 days since 2011. As of 19 August 2019 he still owns at least 31,635 units of Aquestive Therapeutics Inc stock.
You can see the complete history of Mr. Scibetta stock trades at the bottom of the page.
James S. Scibetta serves as Independent Director of the Company. Mr. Scibetta currently serves as Chief Executive Officer and a member of the board of directors of Maverick Therapeutics, Inc., a development stage immuno-oncology company, since July 2017. Prior to Maverick, Mr. Scibetta was appointed President of Pacira Pharmaceuticals, or Pacira (Nasdaq: PCRX), in October 2015, where he oversaw commercial and medical support activities, and directed commercial manufacturing, tech transfer and research and development. Mr. Scibetta served as Pacira’s Chief Financial Officer from 2008 to 2016 where he led its 2011 initial public offering and subsequent debt and equity financings. Prior to that, Mr. Scibetta served as Chief Financial Officer of Bioenvision Inc., a commercial-stage public oncology company acquired by Genzyme, from 2006 to 2007, and Merrimack Pharmaceuticals, an oncology-focused systems biology company, from 2001 to 2006. Earlier in his career, Mr. Scibetta spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. Mr. Scibetta has also served as a director and chairman of the audit committee of Matinas BioPharma Holdings, Inc. (NYSE: MTNB), a biopharmaceutical company, since 2013. Mr. Scibetta received his B.S. in Physics from Wake Forest University and his M.B.A from the University of Michigan. Our Board believes that Mr. Scibetta’s extensive senior management experience in the biotechnology industry, as well as his experience on the boards of both public and private companies, qualifies him to serve on our Board of Directors.
As the Independent Director of Aquestive Therapeutics Inc, the total compensation of James Scibetta at Aquestive Therapeutics Inc is $112,497. There are 7 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.
James Scibetta is 55, he's been the Independent Director of Aquestive Therapeutics Inc since 2017. There are 16 older and 4 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.
James's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER, NJ, 07921.
Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker, and Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.
aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include: